Steroid 5-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders

E-ISSN： 1873-4286|17|2|151-167

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.2, 2011-01, pp. : 151-167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome

Current Pharmaceutical Design, Vol. 20, Iss. 11, 2014-04 ,pp. : 1831-1839

Bentham Science Publishers

Access to resources Recommend Favorite

Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders

By >

Clinical Pharmacokinetics, Vol. 50, Iss. 7, 2011-07 ,pp. : 429-450

Adis International

Access to resources Recommend Favorite

The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 5, Iss. 1, 2006-02 ,pp. : 25-43

Bentham Science Publishers

Access to resources Recommend Favorite

MicroRNAs: A Novel Therapeutic Target for Schizophrenia

Current Pharmaceutical Design, Vol. 17, Iss. 2, 2011-01 ,pp. : 176-188

Bentham Science Publishers

Access to resources Recommend Favorite

Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders

By Vinod K Yaragudri Hungund Basalingappa L

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 2, 2006-04 ,pp. : 203-210

Informa Healthcare

Access to resources Recommend Favorite